FDA clears clinical trial of gene-editing therapy for hemophilia A

Metagenomi’s MGX-001 trial to start in 1st half of next year

Written by Marisa Horak, MS |

An image shows a doctor holding a gene above her head.

Metagenomi's MGX-001 will start clinical trials next year. (Image by iStock)

The U.S. Food and Drug Administration (FDA) has given the go-ahead for Metagenomi Therapeutics to start a first-in-human clinical trial testing MGX-001, the company’s experimental gene-editing therapy for hemophilia A.

The Phase 1/2 trial, dubbed INTEGR8, aims to test the safety and tolerability of MGX-001 and identify optimal dosing strategies for the therapy. The trial is expected to enroll adults with moderately severe to severe hemophilia A, all of whom will receive MGX-001. Metagenomi expects the trial to begin in the first half of 2027, with early data to follow later in the year, according to a company press release.

“We are thrilled to reach this pivotal milestone with the FDA clearance of our [application to start clinical testing] for MGX-001, our lead, wholly owned program in hemophilia A,” said Jian Irish, PhD, president and CEO of Metagenomi.

Hemophilia A is marked by abnormally low levels of factor VIII (FVIII), a protein that’s needed for blood to clot. Lacking FVIII, people with hemophilia A can experience hemophilia symptoms like unusually easy and prolonged bleeding.

MGX-001 is designed to deliver a gene encoding healthy FVIII to the body’s cells, allowing the body to produce an active version of this clotting protein at functional levels. In principle, this mechanism is similar to that of Roctavian (valoctocogene roxaparvovec-rvox), a gene therapy for hemophilia A that was approved in the U.S. and Europe, but was discontinued earlier this year due to low sales and issues with reimbursement.

Recommended Reading
Banner image for

My grandmother had a bleeding story. I had a hemophilia diagnosis.

Delivering the gene

Both MGX-001 and Roctavian are designed to deliver a gene encoding healthy FVIII to cells. But a key difference between the two therapies is exactly how the therapeutic gene is delivered.

With Roctavian, the therapeutic gene is delivered as an episome — that is, a separate chunk of DNA, independent from the cell’s own natural DNA. By contrast, MGX-001 is designed to stick the therapeutic gene directly into a predetermined spot within the cell’s pre-existing DNA.

Specifically, MGX-001 works to insert the therapeutic gene in front of the albumin promoter, a genetic sequence that normally acts like an on switch to help activate a gene that makes a different blood protein. By inserting the therapeutic gene in this spot, MGX-001 aims to harness that on switch to maintain activation of the therapeutic gene, facilitating steady production of FVIII protein to normalize clotting.

MGX-001 itself consists of two parts: a modified virus that delivers the therapeutic gene encoding FVIII, and a nanoparticle that delivers the molecular machinery to insert the gene into the cell’s DNA.

“MGX-001 is designed to leverage our proprietary genome editing platform to integrate a Factor VIII (FVIII) gene site-specifically into the genome, harnessing the power of the body’s native albumin promoter to drive durable, endogenous FVIII production,” Irish said. “This represents an exciting departure from prior approved gene therapy for hemophilia A that relied on episomal FVIII expression.”

According to Metagenomi, testing in animals showed that MGX-001 could increase FVIII activity to within the normal range. There was no evidence of off-target editing or unintended changes to cells’ natural DNA.

“In a landscape with no cure for hemophilia A, we believe MGX-001 has the potential to provide long-term benefit to both adult and pediatric patients,” Irish said.

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.